• Title/Summary/Keyword: Gonadotropin releasing

Search Result 204, Processing Time 0.025 seconds

Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial

  • Shin, Jae Jun;Park, Kyung Eui;Choi, Young Min;Kim, Hye-Ok;Choi, Dong-Hee;Lee, Woo Sik;Cho, Jung-Hyun
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.45 no.3
    • /
    • pp.135-142
    • /
    • 2018

  • Objective: To prospectively evaluate the efficacy and safety of a fixed early gonadotropin-releasing hormone (GnRH) antagonist protocol compared to a conventional midfollicular GnRH antagonist protocol and a long GnRH agonist protocol for in vitro fertilization (IVF) in patients with polycystic ovary syndrome (PCOS). Methods: Randomized patients in all three groups (early antagonist, n = 14; conventional antagonist, n = 11; long agonist, n = 11) received 21 days of oral contraceptive pill treatment prior to stimulation. The GnRH antagonist was initiated on the 1st day of stimulation in the early antagonist group and on the 6th day in the conventional antagonist group. The GnRH agonist was initiated on the 18th day of the preceding cycle. The primary endpoint was the number of oocytes retrieved, and the secondary endpoints included the rate of moderate-to-severe ovarian hyperstimulation syndrome (OHSS) and the clinical pregnancy rate. Results: The median total number of oocytes was similar among the three groups (early, 16; conventional, 12; agonist, 19; p= 0.111). The early GnRH antagonist protocol showed statistically non-significant associations with a higher clinical pregnancy rate (early, 50.0%; conventional, 11.1%; agonist, 22.2%; p= 0.180) and lower incidence of moderate-to-severe OHSS (early, 7.7%; conventional, 18.2%; agonist, 27.3%; p= 0.463), especially among subjects at high risk for OHSS (early, 12.5%; conventional, 40.0%; agonist, 50.0%; p= 0.324). Conclusion: In PCOS patients undergoing IVF, early administration of a GnRH antagonist may possibly lead to benefits due to a reduced incidence of moderate-to-severe OHSS in high-risk subjects with a better clinical pregnancy rate per embryo transfer. Further studies with more subjects are required.

  • https://doi.org/10.5653/cerm.2018.45.3.135 인용 PDF KSCI

Immunocontraceptive Effects in Male Rats Vaccinated with Gonadotropin-Releasing Hormone-I and -II Protein Complex

  • Kim, Yong-Hyun;Park, Byung-Joo;Ahn, Hee-Seop;Han, Sang-Hoon;Go, Hyeon-Jeong;Lee, Joong-Bok;Park, Seung-Yong;Song, Chang-Seon;Lee, Sang-Won;Choi, In-Soo
    • Journal of Microbiology and Biotechnology
    • /
    • v.29 no.4
    • /
    • pp.658-664
    • /
    • 2019

  • Immunocontraception has been suggested as an optimal alternative to surgical contraception in animal species. Many immunocontraceptive vaccines have been designed to artificially produce antibodies against gonadotropin-releasing hormone-I (GnRH-I) which remove GnRH-I from the vaccinated animals. A deficiency of GnRH-I thereafter leads to a lack of gonadotropins, resulting in immunocontraception. In this study, we initially developed three immunocontraceptive vaccines composed of GnRH-I, GnRH-II, and a GnRH-I and -II (GnRH-I+II) complex, conjugated to the external domain of Salmonella Typhimurium flagellin. As the GnRH-I+II vaccine induced significantly (p < 0.01) higher levels of anti-GnRH-I antibodies than the other two vaccines, we further evaluated its immunocontraceptive effects in male rats. Mean testis weight in rats (n = 6) inoculated twice with the GnRH-I+II vaccine at 2-week intervals was significantly (p < 0.01) lower than in negative control rats at 10 weeks of age. Among the six vaccinated rats, two were non-responders whose testes were not significantly reduced when compared to those of negative control rats. Significantly smaller testis weight (p < 0.001), higher anti-GnRH-I antibody levels (p < 0.001), and lower testosterone levels (p < 0.001) were seen in the remaining four responders compared to the negative control rats at the end of the experiments. Furthermore, seminiferous tubule atrophy and spermatogenesis arrest were found in the testis tissues of responders. Therefore, the newly developed GnRH-I+II vaccine efficiently induced immunocontraception in male rats. This vaccine can potentially also be applied for birth control in other animal species.

  • https://doi.org/10.4014/jmb.1901.01067 인용 PDF KSCI

Germ Cell Degeneration during Mammalian Spermatogenesis (포유류의 정자형성과정 중 생식세포의 변화)

  • 김종민
    • Proceedings of the KSAR Conference
    • /
    • 2001.10a
    • /
    • pp.11-13
    • /
    • 2001

  • 사람을 포함한 포유류의 정자형성과정은 시상하부에서 분비된 생식소자극호르몬 방출호르몬 (gonadotropin releasing hormone)의 영향 하에 뇌하수체에서 합성 분비되는 난포자극호르몬 (follicle stimulating hormone; FSH) 과 황체화호르몬 (luteinizing hormone; LH)에 의해서 조절된다. LH의 라이디히 세포 (Leydig cells) 자극으로 인한 testosterone 의 합성분비가 성체(adult)의 정자형성과정과 그 유지(maintenance)에 매우 결정적이다. 반면, FSH는 미성숙 개체의 정소에서 일어나는 예비적 정자형성과정에 있어 중요한 역할을 하며, 성체에서도 질적인 면에서의 정자형성과정에 관여하는 것으로 사려된다. 그러므로, 시상하부-뇌하수체-정소의 축(axis)을 이루는 어느 한 성분에서라도 이상이 생기면 정자의 형성과정은 치명적인 영향을 받을 수 있다. (중략)

  • PDF